ArticleBioMed research international2020
Minimum Clinically Important Difference of Gross Motor Function and Gait Endurance in Children with Motor Impairment: A Comparison of Distribution-Based Approaches.
Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Effectiveness of emerging technology-assisted rehabilitation in children with cerebral palsy: a systematic review and meta-analysis.Frontiers in neurology · 2026Pooled it
- Application of the Gross Motor Function Measure in children with conditions other than cerebral palsy: A systematic review.Developmental medicine and child neurology · 2025Pooled it
- Dual-Task Training Interventions for Cerebral Palsy: A Systematic Review and Meta-Analysis of Effects on Postural Balance and Walking Speed.Medicina (Kaunas, Lithuania) · 2025Pooled it
- The Effects of Trunk Intervention on Gross Motor Function, Balance, and Spasticity in Cerebral Palsy: Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Overground Gait Training With a Wearable Robot in Children With Cerebral Palsy: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Clinical study on the safety and feasibility of AiWalker-K for lower limbs exercise rehabilitation in children with cerebral palsy.PloS one · 2024Trial
- Use of Robot-Assisted Gait Training in Pediatric Patients with Cerebral Palsy in an Inpatient Setting-A Randomized Controlled Trial.Sensors (Basel, Switzerland) · 2022Trial
- A robotic perturbation trainer for transverse-plane gait perturbations in pediatric cerebral palsyMethodsX · 2026Article
- Exoskeleton-assisted physiotherapy in school and outpatient contexts for minimally ambulant children with cerebral palsy.Developmental medicine and child neurology · 2026Article
- Intensive Family-Centered Rehabilitation and Motor Outcomes in a Child with Global Developmental Delay: A Case Report.Children (Basel, Switzerland) · 2026Article
- Treatment for symptomatic hypermobility in childhood.The Cochrane database of systematic reviews · 2026Article
- "Effects of robot-assisted gait training combined with traditional treatment in hereditary spastic paraplegia: An observational pilot cohort study".Scientific reports · 2026Observational
- Habitual Physical Activity and Walking Endurance Following Inpatient Rehabilitation in Children With Cerebral Palsy.Cureus · 2026Article
- Neurorehabilitation and Functional Improvement in Joubert Syndrome: A 12-Month Case Report.Children (Basel, Switzerland) · 2026Article
- Robot-Assisted Gait Training Combined with Conventional Physiotherapy in Postoperative Patients with Diplegic Cerebral Palsy: A Pilot Single Cohort Observational Study.Sensors (Basel, Switzerland) · 2026Observational
- Treatment for primary avascular necrosis of the lower limb in childhood.The Cochrane database of systematic reviews · 2026Article
- Feasibility of a Home-Based Occupational Positioning Program for Children With Spastic Cerebral Palsy: A Preliminary Study.Occupational therapy international · 2026Article
- Effects of active action observation on cognitive, emotional, motor, and somatosensory outcomes in adolescents with juvenile idiopathic arthritis: a prospective exploratory case series.Frontiers in human neuroscience · 2026Article
- Adjunctive dry needling reduces spasticity and improves functional outcomes in children with cerebral palsy: a single-blind randomized controlled trial.Frontiers in pediatrics · 2026Article
- Evaluating the rehabilitative and assistive impact of the Agilik exoskeleton: a pre-post single-group study in children with cerebral palsy.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe minimum clinically important difference (MCID) is a standard way of measuring clinical relevance. The objective of this work was to establish the MCID for the 6-minute walking test (6minWT) and the Gross Motor Function Measure (GMFM-88) in pediatric gait disorders.
methodsA cohort, pretest-posttest study was conducted in a hospitalized care setting. A total of 182 patients with acquired brain injury (ABI) or cerebral palsy (CP) performed 20 robot-assisted gait training sessions complemented with 20 sessions of physical therapy over 4 weeks. Separate MCIDs were calculated using 5 distribution-based approaches, complemented with an anonymized survey completed by clinical professionals.
resultsThe MCID range for the 6minWT was 20-38 m in the ABI cohort, with subgroup ranges of 20-36 m for GMFCS I-II, 23-46 m for GMFCS III, and 24-46 m for GMFCS IV. MCIDs for the CP population were 6-23 m, with subgroup ranges of 4-28 m for GMFCS I-II, 9-19 m for GMFCS III, and 10-27 m for GMFCS IV. For GMFM-88 total score, MCID values were 1.1%-5.3% for the ABI cohort and 0.1%-3.0% for the CP population. For dimension "D" of the GMFM, MCID ranges were 2.3%-6.5% and 0.8%-5.2% for ABI and CP populations, respectively. For dimension "E," MCID ranges were 2.8%-6.5% and 0.3%-4.9% for ABI and CP cohorts, respectively. The survey showed a large interquartile range, but the results well mimicked the distribution-based methods.
conclusionsThis study identified for the first time MCID ranges for 6minWT and GMFM-88 in pediatric patients with neurological impairments, offering useful insights for clinicians to evaluate the impact of treatments. Distribution-based methods should be used with caution: methods based on pre-post correlation may underestimate MCID when applied to patients with small improvements over the treatment period. Our results should be complemented with estimates obtained using consensus- and anchor-based approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.